Medical Director
Midway Immunology and Research Center
Fort Pierce, FL, United States
Dr. Moti Ramgopal is the Founder and Director of Midway Immunology and Research Center as well as the Founder/Chairman of the not-for-profit Midway Specialty Care Center in Florida and Guyana. Additionally, he is a Consultant Physician/Director of Associates in Infectious Diseases and a Clinical Professor at Florida State University College of Medicine. He also serves as an HIV Consultant for the Ministry of Health in the Turks and Caicos Islands. Dr. Ramgopal is passionate about integrating healthcare from developed to underdeveloped communities, especially in the Caribbean, by introducing advancing technologies, clinical research, and trials.
Dr. Ramgopal received his medical degree from the University of the West Indies Faculty of Medical Sciences and has practiced for over 25 years. He is certified by the American Board of Internal Medicine, Board Certified in Infectious Disease, and Fellowship trained in Infectious Diseases. As Principal Investigator at Midway Immunology and Research Center, he has overseen 300+ clinical trials, with his research published in peer-reviewed journals and presented at various national and international conferences. His work has been published in the Lancet, Journal of Clinical Infectious Diseases, and Journal of Acquired Immune Deficiency Syndromes. Additionally, he has presented research at the 2023 International AIDS Society Conference on HIV Science and the Conference on Retroviruses and Opportunistic Infections. Through Midway Specialty Care Center, Dr. Ramgopal and his team embrace the initiative of ending the HIV and HCV pandemics by 2030 in critical communities throughout Florida. To expand the organization's reach, he established two clinics in Georgetown, Guyana, providing the community with new opportunities and access to various laboratory services. Due to his experiences and efforts, US News and World Reports recognized Dr. Ramgopal as a top Infectious Disease Doctor.
Disclosure(s): Gilead Sciences: Advisor/Consultant, Grant/Research Support, Honoraria; Janssen: Advisor/Consultant, Grant/Research Support, Honoraria; Merck: Advisor/Consultant, Grant/Research Support; ViiV Healthcare: Advisor/Consultant, Grant/Research Support, Honoraria
505 - Real-World Use of Cabotegravir Long-Acting for Pre-Exposure Prophylaxis: Data from Trio Health Cohort
Saturday, October 19, 2024
10:45 AM – 11:00 AM US PT